$2.48
0.2511.21%
At close: -
$2.51
0.031.21%
After Hours: 7:32 PM EDT
Comments
Loading...
Vivos Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:VVOS | Benzinga
Vivos Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 13
EPS Estimate
$-0.360
Quarterly Revenue Estimate
$3.63M
Annual Revenue
(as of Dec 31)
(as of Dec 31)
$15.03M
Analyze the earnings history of Vivos Therapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| VVOS | Vivos Therapeutics | -$1.63 | -$0.36 | — | — | $3.42M | $3.63M | — | — | 05/13/2025 | Get Alert |
| VVOS | Vivos Therapeutics | -$3.05 | -$0.43 | -$0.28 | 34.88% | $3.25M | $3.89M | $3.70M | -4.94% | 03/31/2025 | Get Alert |
| VVOS | Vivos Therapeutics | -$1.75 | -$0.70 | -$0.40 | 42.86% | $3.30M | $4.18M | $3.86M | -7.66% | 11/14/2024 | Get Alert |
| VVOS | Vivos Therapeutics | -$0.18 | -$1.05 | -$0.60 | 42.86% | $3.40M | $3.60M | $4.05M | 12.61% | 08/14/2024 | Get Alert |
| VVOS | Vivos Therapeutics | -$1.72 | — | -$1.63 | — | $3.86M | — | $3.42M | — | 05/14/2024 | Get Alert |
| VVOS | Vivos Therapeutics | -$5.00 | -$1.90 | -$3.05 | -60.53% | $3.95M | $3.41M | $3.25M | -4.75% | 03/28/2024 | Get Alert |
| VVOS | Vivos Therapeutics | -$6.50 | — | -$1.75 | — | $4.25M | — | $3.30M | — | 11/14/2023 | Get Alert |
| VVOS | Vivos Therapeutics | -$8.25 | -$3.50 | -$4.50 | -28.57% | $4.18M | $4.15M | $3.40M | -18.19% | 08/16/2023 | Get Alert |
| VVOS | Vivos Therapeutics | -$6.50 | -$4.50 | -$5.00 | -11.11% | $3.46M | $4.01M | $3.86M | -3.82% | 06/08/2023 | Get Alert |
| VVOS | Vivos Therapeutics | -$8.50 | -$5.50 | -$5.00 | 9.09% | $4.39M | $4.55M | $3.95M | -13.19% | 03/30/2023 | Get Alert |
| VVOS | Vivos Therapeutics | -$4.75 | — | -$8.25 | — | $4.50M | $3.81M | $4.18M | 9.82% | 12/20/2022 | Get Alert |
| VVOS | Vivos Therapeutics | -$6.50 | — | -$6.50 | — | $4.55M | $3.72M | $4.25M | 14.14% | 12/20/2022 | Get Alert |
| VVOS | Vivos Therapeutics | -$4.75 | -$6.50 | -$6.50 | 0.00% | $3.45M | $4.44M | $3.46M | -22.07% | 05/16/2022 | Get Alert |
| VVOS | Vivos Therapeutics | -$12.00 | — | -$8.50 | — | $3.30M | — | $4.39M | — | 03/31/2022 | Get Alert |
| VVOS | Vivos Therapeutics | -$4.25 | -$4.50 | -$6.50 | -44.44% | $3.29M | $4.50M | $4.55M | 1.02% | 11/15/2021 | Get Alert |
| VVOS | Vivos Therapeutics | — | -$4.50 | -$4.75 | -5.56% | — | $3.60M | $4.50M | 24.92% | 08/12/2021 | Get Alert |
| VVOS | Vivos Therapeutics | -$5.75 | — | -$4.75 | — | $3.20M | — | $3.45M | — | 05/17/2021 | Get Alert |
| VVOS | Vivos Therapeutics | — | -$4.00 | -$12.00 | -200.00% | $3.10M | $3.21M | $3.30M | 2.80% | 03/25/2021 | Get Alert |
Vivos Therapeutics (VVOS) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-03-31 | $-0.28 | $-0.43 | 34.9 % |
| Q3 | 2024-11-14 | $-0.40 | $-0.70 | 42.9 % |
| Q2 | 2024-08-14 | $-0.60 | $-1.05 | 42.9 % |
| Q4 | 2024-03-28 | $-3.05 | $-1.90 | -60.5 % |
Vivos Therapeutics (VVOS) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-03-31 | $3.70M | $3.89M | -4.94 % |
| Q3 | 2024-11-14 | $3.86M | $4.18M | -7.66 % |
| Q2 | 2024-08-14 | $4.05M | $3.60M | 12.6 % |
| Q4 | 2024-03-28 | $3.25M | $3.41M | -4.75 % |
FAQ
When is Vivos Therapeutics (NASDAQ:VVOS) reporting earnings?
Vivos Therapeutics (VVOS) is scheduled to report earnings on May 13, 2025. The last reported earnings were for reported on March 31, 2025 for Q4.
What were the latest earnings per share (EPS) for Vivos Therapeutics (NASDAQ:VVOS)?
The Actual EPS was $-0.28, which beat the estimate of $-0.43.
What were Vivos Therapeutics’s (NASDAQ:VVOS) revenues?
The Actual Revenue was $3.7M, which missed the estimate of $3.9M.
Browse earnings estimates, EPS, and revenue on all stocks.